Support Services

The Kcentra hotline (18554KCENTRA) is available 24 hours a day, 7 days a week for additional product information, medical inquiries, reimbursement support, and resources

CSL Behring Commitment

CSL Behring, a leader in coagulation therapies, has a long-standing commitment to safety and quality.

  • Committed to saving lives and improving the lives of people with rare and serious diseases, the company manufactures and markets a range of plasma-derived and recombinant therapies worldwide.
  • CSL Behring is committed to maintaining the highest standards of quality and safety throughout the production process. Our integrated safety system ensures that only the highest quality plasma is selected for use in manufacturing and only safe and effective therapies are released.
  • Quality control measures, including extensive inspections, tests and cross-checks are performed by highly trained personnel at each stage in the manufacturing process.

Kcentra Product Support

The Kcentra Hotline, with live 24/7 support for an immediate response, provides exceptional support from CSL Behring. Kcentra Hotline representatives are able to answer on-label medical questions as well as product questions, which distinguishes it from other product hotlines.

Speak with a Kcentra Hotline representative for:

  • Product information
  • Medical inquiries
  • Reimbursement support
  • Resources

For example, if you want to order Kcentra and need to know which distributors carry it, call the hotline. If you have on-label product support questions, the hotline can answer those for you. If you have questions about how to get reimbursed for Kcentra, the hotline will be glad to help you with that.

Medical Question Support

The ability of Kcentra Hotline representatives to answer medical and treatment questions differentiates them from other hotlines that are strictly for product information and ordering/reimbursement support.

  • If you have a question while you are treating a patient, and want to talk with a healthcare professional, you can call the Kcentra hotline 24/7 at 1-855-452-3687.
  • If your patient has an adverse reaction to the product, contact or have them contact CSL Behring Pharmacovigilance at 1-866-915-6958; for any other concern related to treatment with Kcentra, you can call the Kcentra hotline at 1-855-452-3687 to speak with them about how to proceed.

If you need materials to train your staff on how to properly dose and administer Kcentra, call the hotline to discuss the available resources.

Home Support Services Support Services

Important Safety Information

Kcentra®, Prothrombin Complex Concentrate (Human), is a blood coagulation factor replacement product indicated for the urgent reversal of acquired coagulation factor deficiency induced by Vitamin K antagonist (VKA—eg, warfarin) therapy in adult patients with acute major bleeding or the need for urgent surgery or other invasive procedure. Kcentra is for intravenous use only.


Patients being treated with Vitamin K antagonist therapy have underlying disease states that predispose them to thromboembolic events. Potential benefits of reversing VKA should be weighed against the risk of thromboembolic events, especially in patients with history of such events. Resumption of anticoagulation therapy should be carefully considered once the risk of thromboembolic events outweighs the risk of acute bleeding. Both fatal and nonfatal arterial and venous thromboembolic complications have been reported in clinical trials and postmarketing surveillance. Monitor patients receiving Kcentra, and inform them of signs and symptoms of thromboembolic events. Kcentra was not studied in subjects who had a thromboembolic event, myocardial infarction, disseminated intravascular coagulation, cerebral vascular accident, transient ischemic attack, unstable angina pectoris, or severe peripheral vascular disease within the prior 3 months. Kcentra might not be suitable for patients with thromboembolic events in the prior 3 months.

Kcentra is contraindicated in patients with known anaphylactic or severe systemic reactions to Kcentra or any of its components (including heparin, Factors II, VII, IX, X, Proteins C and S, Antithrombin III and human albumin). Kcentra is also contraindicated in patients with disseminated intravascular coagulation. Because Kcentra contains heparin, it is contraindicated in patients with heparin-induced thrombocytopenia (HIT).

Hypersensitivity reactions to Kcentra may occur. If patient experiences severe allergic or anaphylactic type reactions, discontinue administration and institute appropriate treatment.

In clinical trials, the most frequent (≥2.8%) adverse reactions observed in subjects receiving Kcentra were headache, nausea/vomiting, hypotension, and anemia. The most serious adverse reactions were thromboembolic events, including stroke, pulmonary embolism and deep vein thrombosis.

Kcentra is made from human blood and may carry a risk of transmitting infectious agents, e.g., viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent, and theoretically, the Creutzfeldt-Jakob disease (CJD) agent.

Please see full prescribing information for Kcentra.

CSL Behring
Kcentra is manufactured by CSL Behring GmbH and distributed by CSL Behring LLC.
Kcentra® and Beriplex® are registered trademarks of CSL Behring GmbH.
Biotherapies for Life® is a registered trademark of CSL Behring LLC
All other products mentioned are trademarks or registered trademarks of their respective companies.
© 2017 CSL Behring. The product information presented on this site is intended for US residents only.
KCT15-11-0051 12/2015